Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life
Bavarian Nordic will get an accelerated review of its chikungunya vaccine CHIKV VLP at the EMA, as it tries to chase down a lead held by rival Valneva.
Valneva has claimed the accolade of becoming the first drugmaker to win FDA approval for a vaccine for chikungunya virus, a potentially life-threatening mosquito-borne dis
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
With an FDA decision in its marketing application for chikungunya vaccine VLA1553 just a couple of months away, Valneva has published data reinforcing the clinical evidenc
Valneva has moved a step closer to its goal of becoming the first company to file for approval of a vaccine against chikungunya virus in the US after reporting new clinical data today.